Cargando…
Caplacizumab Model‐Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare and life‐threatening autoimmune thrombotic microangiopathy. Caplacizumab, evaluated in phase II and III studies in adults, shortens the time to platelet count response and reduces aTTP exacerbations, has a favorable safety profile, and ca...
Autores principales: | Bergstrand, Martin, Hansson, Emma, Delaey, Bernard, Callewaert, Filip, De Passos Sousa, Rui, Sargentini‐Maier, Maria Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255589/ https://www.ncbi.nlm.nih.gov/pubmed/34699078 http://dx.doi.org/10.1002/jcph.1991 |
Ejemplares similares
-
Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020) -
Caplacizumab in adult patients with acquired thrombotic
thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020) -
Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021) -
Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)